Natural killer cell group 2 member D receptor (NKG2D)

The Natural killer cell group 2 member D receptor (NKG2D) is a type II transmembrane, activating immune cell receptor belonging to the C-type lectin-like receptor family. It is encoded by the KLRK1 gene and is expressed on all NK cells, cytokine-induced killer (CIK) cells, and subsets of T cells (notably CD8+ T cells and γδ T cells). NKG2D mediates its effects by recognizing a range of stress-induced ligands (including MICA, MICB, and ULBP family proteins) expressed on transformed, infected, or otherwise stressed cells, thus triggering NK and CIK cell cytotoxicity and the release of pro-inflammatory cytokines[1][2][3][4][5][6][7][8]. NKG2D relies on the adaptor protein DAP10 for intracellular signaling, leading to activation of PI3K-, PLC-γ-, and Src-family kinase pathways[1][3]. It serves a pivotal role in cancer immunosurveillance and immunity against infections but is also implicated in autoimmunity and immune escape mechanisms. Several experimental therapeutic strategies—including NKG2D blockade, ligand modulation, and cellular therapies—are under investigation for modulating this axis in cancer and immune disorders.

Other names

Killer cell lectin-like receptor subfamily K, member 1KLRK1CD314NK cell group 2, member DNKG2-DNatural killer cell group 2, member D

Recognition and binding of NKG2D ligands (e.g., MICA/B, ULBPs) on target cells triggers NK/CIK activation, cytotoxicity, and cytokine release through the DAP10 signaling adaptor. Augmentation of antibody-dependent cellular cytotoxicity (via NKG2D co-activation of CD16 in NK cells). Synergistic activation with other receptors, particularly 2B4, NKp46, and CD16.